Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BHCNASDAQ:REGNNYSE:SNAP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHCBausch Health Cos$6.95-2.4%$5.25$3.96▼$9.85$2.63B0.412.62 million shs1.18 million shsREGNRegeneron Pharmaceuticals$545.00-0.5%$551.63$476.49▼$1,211.20$59.14B0.33905,431 shs456,413 shsSNAPSnap$9.27-1.2%$8.45$7.08▼$17.33$15.68B0.5930.64 million shs21.79 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHCBausch Health Cos+4.56%+11.44%+58.53%+25.29%0.00%REGNRegeneron Pharmaceuticals+2.40%+5.28%+11.60%-10.30%-47.57%SNAPSnap0.00%+17.08%+14.47%+16.57%-42.25%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBHCBausch Health Cos3.7777 of 5 stars0.93.00.04.03.13.31.9REGNRegeneron Pharmaceuticals4.9529 of 5 stars4.45.01.72.33.21.71.9SNAPSnap3.6737 of 5 stars4.12.00.00.03.33.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBHCBausch Health Cos 1.86Reduce$7.426.73% UpsideREGNRegeneron Pharmaceuticals 2.80Moderate Buy$813.5749.28% UpsideSNAPSnap 2.23Hold$35.74285.80% UpsideCurrent Analyst Ratings BreakdownLatest REGN, SNAP, and BHC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/1/2025SNAPSnapWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$8.00 ➝ $11.006/30/2025REGNRegeneron PharmaceuticalsArgusSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold6/9/2025REGNRegeneron PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$950.00 ➝ $800.006/5/2025REGNRegeneron PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$633.00 ➝ $560.006/2/2025REGNRegeneron PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$700.00 ➝ $650.006/2/2025REGNRegeneron PharmaceuticalsBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$800.00 ➝ $600.006/2/2025REGNRegeneron PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$958.00 ➝ $755.005/30/2025REGNRegeneron PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/30/2025REGNRegeneron PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeModerate Buy ➝ Hold$662.005/30/2025REGNRegeneron PharmaceuticalsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight$700.00 ➝ $580.005/27/2025REGNRegeneron PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Sector Perform$943.00 ➝ $662.00(Data available from 7/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBHCBausch Health Cos$9.63B0.27$7.55 per share0.92($0.89) per share-7.81REGNRegeneron Pharmaceuticals$14.20B4.14$45.49 per share11.98$268.50 per share2.03SNAPSnap$5.36B2.89N/AN/A$1.47 per share6.30Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBHCBausch Health Cos-$46M-$0.11N/A1.49N/A-0.41%-540.45%5.26%7/30/2025 (Estimated)REGNRegeneron Pharmaceuticals$4.41B$39.2813.8714.332.0131.94%15.27%11.93%7/30/2025 (Estimated)SNAPSnap-$697.86M-$0.31N/AN/AN/A-9.63%-21.53%-6.37%7/30/2025 (Estimated)Latest REGN, SNAP, and BHC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/29/2025Q1 2025REGNRegeneron Pharmaceuticals$8.83$8.22-$0.61$7.27$3.40 billion$3.03 billion4/29/2025Q1 2025SNAPSnap$0.04-$0.08-$0.12-$0.08$1.35 billion$1.36 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBHCBausch Health CosN/AN/AN/AN/AN/AREGNRegeneron Pharmaceuticals$3.520.65%N/A8.96%N/ASNAPSnapN/AN/AN/AN/AN/ALatest REGN, SNAP, and BHC DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/20/2025REGNRegeneron Pharmaceuticalsquarterly$0.880.6%5/20/20255/20/20256/6/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBHCBausch Health CosN/A1.350.97REGNRegeneron Pharmaceuticals0.094.934.03SNAPSnap1.554.304.30Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBHCBausch Health Cos78.65%REGNRegeneron Pharmaceuticals83.31%SNAPSnap47.52%Insider OwnershipCompanyInsider OwnershipBHCBausch Health Cos8.05%REGNRegeneron Pharmaceuticals7.02%SNAPSnap22.68%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBHCBausch Health Cos20,700370.08 million340.29 millionOptionableREGNRegeneron Pharmaceuticals15,106107.96 million100.39 millionOptionableSNAPSnap4,9111.67 billion1.29 billionOptionableREGN, SNAP, and BHC HeadlinesRecent News About These CompaniesSnap (SNAP) Stock Falls Amid Market Uptick: What Investors Need to Know3 hours ago | zacks.comSnap's Quiet Comeback: Finally Getting Its Act Together?July 3 at 11:01 AM | seekingalpha.comSnap Inc. (NYSE:SNAP) General Counsel Sells $209,040.00 in StockJuly 3 at 6:49 AM | insidertrades.comSnapchat: Margin Expansion Will Power The Snap-BackJuly 3 at 6:01 AM | seekingalpha.comSumitomo Mitsui Trust Group Inc. Sells 50,188 Shares of Snap Inc. (NYSE:SNAP)July 3 at 4:24 AM | marketbeat.comRobeco Institutional Asset Management B.V. Has $225,000 Stock Holdings in Snap Inc. (NYSE:SNAP)July 3 at 4:03 AM | marketbeat.comWells Fargo & Company Forecasts Strong Price Appreciation for Snap (NYSE:SNAP) StockJuly 3 at 3:39 AM | americanbankingnews.comInsider Selling: Snap Inc. (NYSE:SNAP) General Counsel Sells 24,000 Shares of StockJuly 2 at 8:52 PM | marketbeat.comSnap (SNAP) Surges 7.6%: Is This an Indication of Further Gains?July 2 at 9:35 AM | zacks.comWhat's Going On With Snap Shares Today?July 1 at 4:16 PM | benzinga.comWells Fargo & Company Raises Snap (NYSE:SNAP) Price Target to $11.00July 1 at 10:46 AM | marketbeat.comLos Angeles Social Media Firm Snap Acquires Calendar App SaturnJune 30 at 8:52 PM | latimes.comBuy, Sell, Or Hold SNAP Stock At $9?June 30 at 10:03 AM | forbes.comIAS Launches First-to-Market AI-Powered Social Attention Measurement for SnapJune 30 at 8:00 AM | prnewswire.comIllinois Municipal Retirement Fund Increases Stake in Snap Inc. (NYSE:SNAP)June 29, 2025 | marketbeat.comPerpetual Ltd Buys 46,459 Shares of Snap Inc. (NYSE:SNAP)June 29, 2025 | marketbeat.comSnap Sees Unusually Large Options Volume (NYSE:SNAP)June 29, 2025 | americanbankingnews.comSnap (SNAP) Surges 7.13% on Bullish Analyst RatingJune 28, 2025 | insidermonkey.comSnap Inc. (NYSE:SNAP) Receives $35.62 Average Price Target from AnalystsJune 28, 2025 | americanbankingnews.comWhy Snap Stock Soared TodayJune 27, 2025 | fool.comSnap stock: 3 reasons why it looks better than a Christmas treat right nowJune 27, 2025 | invezz.comINew MarketBeat Followers Over TimeMedia Sentiment Over TimeREGN, SNAP, and BHC Company DescriptionsBausch Health Cos NYSE:BHC$6.95 -0.17 (-2.40%) Closing price 03:56 PM EasternExtended Trading$6.96 +0.01 (+0.09%) As of 04:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.Regeneron Pharmaceuticals NASDAQ:REGN$545.00 -2.74 (-0.50%) Closing price 03:59 PM EasternExtended Trading$547.81 +2.81 (+0.52%) As of 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.Snap NYSE:SNAP$9.26 -0.12 (-1.23%) Closing price 03:58 PM EasternExtended Trading$9.27 +0.00 (+0.05%) As of 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Snap Inc. operates as a technology company in North America, Europe, and internationally. The company offers Snapchat, a visual messaging application with various tabs, such as camera, visual messaging, snap map, stories, and spotlight that enable people to communicate visually through short videos and images. It also provides Spectacles, an eyewear product that connects with Snapchat and captures photos and video from a human perspective; and advertising products, including AR ads and Snap ads comprises a single image or video ads, collection ads, dynamic ads, story ads, and commercials. The company was formerly known as Snapchat, Inc. and changed its name to Snap Inc. in September 2016. Snap Inc. was founded in 2010 and is headquartered in Santa Monica, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Nike's Stock Just Got an Upgrade: Is a Real Comeback Brewing? Why Hims & Hers Is a Buy Below $35 After Its 16% Pullback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
